Detection of Nausea-Like Response in Rats by Monitoring Facial Expression

Kouichi Yamamoto *, Soichi Tatsutani and Takayuki Ishida

Division of Health Sciences, Department of Medical Science and Technology, Graduate School of Medicine, Osaka University, Osaka, Japan

Patients receiving cancer chemotherapy experience nausea and vomiting. They are not life-threatening symptoms, but their insufficient control reduces the patients’ quality of life. To identify methods for the management of nausea and vomiting in preclinical studies, the objective evaluation of these symptoms in laboratory animals is required. Unlike vomiting, nausea is defined as a subjective feeling described as recognition of the need to vomit; thus, determination of the severity of nausea in laboratory animals is considered to be difficult. However, since we observed that rats grimace after the administration of cisplatin, we hypothesized that changes in facial expression can be used as a method to detect nausea. In this study, we monitored the changes in the facial expression of rats after the administration of cisplatin and investigated the effect of anti-emetic drugs on the prevention of cisplatin-induced changes in facial expression.

Rats were housed in individual cages with free access to food and tap water, and their facial expressions were continuously recorded by infrared video camera. On the day of the experiment, rats received cisplatin (0, 3, and 6 mg/kg, i.p.) with or without a daily injection of a 5-HT3 receptor antagonist (granisetron: 0.1 mg/kg, i.p.) or a neurokinin NK1 receptor antagonist (fosaprepitant: 2 mg/kg, i.p.), and their eye-opening index (the ratio between longitudinal and axial lengths of the eye) in the recorded video image was calculated. Cisplatin significantly and dose-dependently induced a decrease of the eye-opening index 6 h after the cisplatin injection, and the decrease continued for 2 days. The acute phase (day 1), but not the delayed phase (day 2), of the decreased eye-opening index was inhibited by treatment with granisetron; however, fosaprepitant abolished both phases of changes. The time-course of changes in facial expression are similar to clinical evidence of cisplatin-induced nausea in humans. These findings indicate that the monitoring of facial expression has the potential to be useful for the detection of a nausea-like response in laboratory animals.

Keywords: chemotherapy-induced nausea, facial expression, infrared video camera, rats, neurokinin NK1 receptor antagonist, serotonin 5-HT3 receptor antagonist

INTRODUCTION

Cisplatin-based cancer chemotherapy often induces a biphasic pattern of nausea and vomiting, which are classified as the acute phase (within 24 h following drug administration) and delayed phase (24 h after drug administration) (Navari, 2015). To reduce these symptoms, serotonin 5-HT3 receptor antagonists, neurokinin NK1 receptor antagonists, and corticosteroids are used (Jordan et al., 2015; Natale, 2015; Einhorn et al., 2016; Navari and Aapro, 2016). This regimen proved to

Citation:
Yamamoto K, Tatsutani S and Ishida T (2017) Detection of Nausea-Like Response in Rats by Monitoring Facial Expression. Front. Pharmacol. 7:534, doi: 10.3389/fphar.2016.00534
be significantly effective, but patients still experience nausea, especially delayed nausea (Molassiotis et al., 2008; Farrell et al., 2013). Nausea is not life-threatening, but its insufficient control is a definite factor reducing the patients’ quality of life (Bloechl-Daum et al., 2006; Farrell et al., 2013; Navari, 2015).

To identify methods to manage chemotherapy-induced nausea and vomiting in preclinical studies, an objective and precise method to evaluate nausea and vomiting in laboratory animals is required. Vomiting is defined as the involuntary and forceful expulsion of the stomach contents through the mouth (Quigley et al., 2001); therefore, animal species which possess a vomiting reflex, such as ferrets, dogs, cats, and *Suncus murinus*, are used as laboratory animals for its study, because the vomiting reflex is a readily detectable behavior (Florczyk et al., 1982; Ueno et al., 1987; King, 1990). Unlike vomiting, nausea is defined as an unpleasant feeling in the upper gastrointestinal tract with an involuntary urge to vomit (Quigley et al., 2001); thus, it is difficult to recognize whether laboratory animals feel nausea even with the use of vomiting species. Rats, one of the most common laboratory animals, have been considered unsuitable for the study of nausea and vomiting because they do not show a vomiting reflex (Hatcher, 1924). We previously reported that pica behavior, a behavior seen in rats characterized by eating non-nutritive materials, such as clay (kaolin), has been considered as a model of a nausea-like response or gastrointestinal malaise because it is induced by nauseant stimuli and the amount of kaolin intake is related to the nauseant severity in humans (Yamamoto et al., 2007, 2011, 2014, 2015, 2016). However, previous studies reported that it is difficult to evaluate their nausea-like response by the amount of kaolin intake, because rats subjected to marked stimuli showed decreased feeding and locomotive behaviors due to

![Figure 1](image_url)
behavioral suppression (Malik et al., 2006, 2007; Cabezos et al., 2008).

Alternatively, since we observed that rats grimaced after the administration of cisplatin, we hypothesized that changes in facial expression could be used as a method to detect a nausea-like response in rats. In this study, we monitored the changes in the facial expression of rats after the administration of cisplatin and investigated the effect of anti-emetic drugs on the prevention of these cisplatin-induced changes.

MATERIALS AND METHODS

General Procedure
All experiments were approved by the Animal Care Committee of the School of Allied Health Sciences, Faculty of Medicine, Osaka University (26-05-01), and were conducted in accordance with the Animal Experiment Guidelines of Osaka University. Female Wistar/ST rats (8 weeks old, body weight: 180–210 g) were obtained from Japan SLC (Shizuoka, Japan) and housed in individual home cages (25 cm × 20 cm × 20 cm) in a room with a regular light/dark cycle (lights on 0600–1800 h) at a constant temperature (approximately 24°C) and humidity (approximately 50%). One of the risk factors of chemotherapy-induced nausea and vomiting is considered to be a female sex (du Bois et al., 1992). We previously reported that female rats are more susceptible to the induction of sevoflurane-induced pica behavior than male rats (Yamamoto et al., 2016); thus, we used only female rats in a series of experiments. They were allowed free access to tap water and commercially available standard chow (CE-2, CLEA Japan, Inc., Tokyo, Japan). During habituation and the experimental period, the home cage was rotated in a clockwise-direction at a rate of one degree per second using a turntable (S-series, Sigma Planning Corporation, Tokyo, Japan) in order to confirm the facial expression. On the day of the experiment, rats intraperitoneally (i.p.) received cisplatin (3 or 6 mg/kg) at a volume of 6 mL/kg at 1800 h and the entire home cage was continuously recorded on motion video (30 frames per second) by an infrared camera (CS-W70HD, Planex Communications, Inc., Tokyo, Japan), which was placed 30 cm away from home cage surface, for 2 days after the injection of cisplatin (see Figure 1A). The doses and injection time of cisplatin selected in this experiment were determined based on our previous published data (Yamamoto et al., 2014). Controls were treated with saline (6 mL/kg body weight, i.p.). At the end of the experiment, all animals were euthanized by the intraperitoneal injection of an overdose of sodium pentobarbital (150 mg/kg). There were six rats in each of the experimental groups.

Measurement of Eye-Opening Index
Frame images in the recorded motion video were analyzed by frame-by-frame playback for 5 min every 15 min, and an image of the left lateral side of each rat’s face in the analyzed part
of the video was selected and captured. The longitudinal and axial lengths of the eye (Figure 1B) in the captured images were measured by ImageJ analysis software (Version 1.48: developed by Wayne Rasbands, National Institutes of Health, Bethesda, MD, USA), and then the ratio between the longitudinal and axial lengths of the eye (eye-opening index) was calculated, and the three-hourly average of eye-opening index was measured.

Effects of the 5-HT\textsubscript{3} or NK\textsubscript{1} Receptor Antagonist on the Cisplatin-Induced Nausea-Like Response in Rats

Rats were administered granisetron (5-HT\textsubscript{3} receptor antagonist, 0.1 mg/kg, i.p.) or fosaprepitant (NK\textsubscript{1} receptor antagonist, 2 mg/kg, i.p.) 30 min before and 24 h after the administration of cisplatin (3 or 6 mg/kg, i.p.). The doses of granisetron and fosaprepitant selected in this experiment were determined based on our previous published data (Yamamoto et al., 2014). Then, the eye-opening index was obtained using the same method as in previous experiment, and the three-hourly average of eye-opening index was analyzed. Control animals received saline (0.1 ml/100 g body weight, i.p.) as a vehicle.

Cisplatin-Induced Pica Behavior in Rats

To determine the profile of cisplatin-induced pica behavior and anorexia in female rats, we used an automatic kaolin and food intake monitoring system (FDM700SW, Melquest, Toyama, Japan) that we previously developed (Yamamoto et al., 2011). Briefly, this system is an apparatus to determine the amount of kaolin and food intakes in rats automatically consisting of an acrylic home cage (26 cm × 20 cm × 23 cm), two containers (7 cm × 4 cm × 10 cm), and a controller equipped with two load cells (weight sensor). Kaolin and food pellets (CE-2, CLEA Japan, Tokyo, Japan) were provided in their respective containers. Rats were adapted to the experimental environment for 7 days and allowed free access to tap water and both pellets throughout the experimental period. Kaolin and food intakes were monitored hourly to the nearest 0.01 g and the data were stored and analyzed using a laptop PC. Kaolin pellets were prepared according to a previously reported method (Yamamoto et al., 2011). On the day of the experiment, rats received cisplatin (3 or 6 mg/kg, i.p.) with or without granisetron or fosaprepitant, and their three hourly rates of kaolin and food consumption were measured for 2 days after the injection of cisplatin. Controls were treated with saline (i.p.). The protocol of drug administration was identical to those of experiment on measurement of eye-opening index. There were six rats in each of the experimental groups.

Drugs

Cisplatin [cis-Diamineplatinum(II) dichloride: Sigma-Aldrich, St. Louis, MO, USA], granisetron hydrochloride (Kytril\textsuperscript{R} inj. Chugai-Roche Diagnostics Japan, Tokyo, Japan), and fosaprepitant dimeglumine (Proemend\textsuperscript{R}; Ono Pharmaceutical,
Osaka) were purchased through a pharmaceutical agency (Katayama Chemical Industries, Osaka, Japan) and dissolved in physiological saline. All drugs were prepared immediately before injection. Gum arabic (Sigma-Aldrich Japan, Tokyo, Japan) and kaolin (Sigma-Aldrich Japan) were also purchased through Katayama Chemical Industries. Doses are expressed as the free base.

**Statistical Analysis**

The data are expressed as the mean value ± SEM. Differences in the results of the eye-opening index were analyzed using the two-way repeated measure analysis of variance (ANOVA), followed by post hoc Bonferroni’s test. Differences in the results of kaolin and food intake were analyzed using the one-way ANOVA, followed by post hoc Dunnett’s multiple comparison test. A P-value of less than 0.05 was considered significant.

**RESULTS**

**Effects of Cisplatin on Eye-Opening Index in Rats**

Although rats move about in their home cage at all hours of the day and night, the rotation of the cage using a turntable allowed us to record each rat’s facial expression. As shown in Figure 2, there was a prominent circadian variation in the eye-opening index of control rats. The values in the rats’ dark-active phase were significantly higher than those in the light-inactive phase, and a similar tendency was observed on the following day. Cisplatin at doses of 3 and 6 mg/kg significantly and dose-dependently decreased the eye-opening index. These decreases were observed within 6 and 3 h after cisplatin administration, respectively. Although the decrease continued throughout the entire observation period, the values in rats treated with cisplatin at a dose of 6 mg/kg were significantly lower than those in rats treated with cisplatin at a dose of 3 mg/kg.

**Effects of 5-HT₃ and NK₁ Receptor Antagonists on Cisplatin-Induced Decrease of Eye-Opening Index in Rats**

Granisetron and fosaprepitant alone did not affect the eye-opening index throughout the entire period. The decrease of the eye-opening index induced within 24 h after the injection of cisplatin at a dose of 3 mg/kg was effectively inhibited by pretreatment with granisetron, but the decrease on the second day of cisplatin administration was not completely recovered by the daily administration of granisetron (Figure 3). On the other hand, pretreatment with fosaprepitant completely abolished both phases of cisplatin (3 mg/kg)-induced decrease of the eye-opening index. The daily administration of granisetron did not improve the decrease of the eye-opening index induced by cisplatin at a dose of 6 mg/kg throughout the entire period (Figure 4). However, the administration of fosaprepitant significantly inhibited the cisplatin (6 mg/kg)-induced decrease of the eye-opening index.

![FIGURE 4 | Effects of anti-emetic drugs on the eye-opening index in rats treated with cisplatin (6 mg/kg).](image-url)
Effects of Cisplatin on Pica Behavior in Rats

As shown in Figures 5A,B, cisplatin at a dose of 3 mg/kg induced pica behavior and anorexia, and these behaviors were continued for 2 days. These behaviors were observed within 3 and 12 h after administration, respectively. On the other hand, cisplatin at a dose of 6 mg/kg did not induce pica behavior because all rats ate a small amount of food (less than 7 g) during the observation period due to severe anorexia. Granisetron and fosaprepitant alone did not affect kaolin or food intake. The pica behavior elicited within 24 h after cisplatin (3 mg/kg) administration was effectively inhibited by pretreatment with granisetron, but the daily administration of granisetron did not inhibit pica induced beyond 24 h after cisplatin administration (Figure 6A) or anorexia throughout the entire observation period (Figure 6B). However, pretreatment with fosaprepitant abolished both phases of pica and anorexia (Figures 6A,B). Neither antiemetic drug affected kaolin intake in rats treated with cisplatin at a dose of 6 mg/kg; however, pretreatment with fosaprepitant, but not granisetron, significantly improved cisplatin-induced anorexia (Figures 7A,B), although all rats administered cisplatin at a dose of 6 mg/kg showed severe anorexia.

DISCUSSION

Quantifying nausea in humans generally involves using a 100-mm visual analog scale (VAS), which is common in pain...
confirmed that rats treated with cisplatin at a dose of 6 mg/kg we could not evaluate the effect of the higher dose of cisplatin by the lower dose of cisplatin. On the other hand, although drugs did not show these changes and pica behavior induced Furthermore, we observed that rats pretreated with anti-emetic is similar to the latency of cisplatin-induced nausea in humans. The amount of kaolin intake in rats is proportional to the emetogenicity in humans (Yamamoto et al., 2007). We also found that there are sex differences in cisplatin-induced pica in rats because cisplatin at a dose of 3 mg/kg significantly induced pica in female but not male rats (Yamamoto et al., 2014). However, we often could not evaluate their nausea by the amount of kaolin intake because rats that received severe emetic stimuli showed decrease of feeding and locomotive behavior due to behavioral suppression. We actually found that no rats administered cisplatin at a dose of 6 mg/kg ate more than 7 g of standard chow and 1 g of kaolin. Moreover, the anorexia induced by cisplatin at a dose of 6 mg/kg was resistant to premedication with anti-emetic drugs. Similar results were also observed by Malik et al. (2006, 2007) and Cabezos et al. (2008). Pain is also defined as an unpleasant sensory and emotional experience associated with potential tissue damage (Ripamonti, 2012). Since we can measure its severity from a patients’ subjective report, it is also considered that the accurate evaluation of pain in animals remains impossible. Previous reports demonstrated that spontaneous pain in animals such as rats, mice, horses, and rabbits could be evaluated using the changes of facial expressions, and that patients with severe nausea change their facial expression to signify distress (Langford et al., 2010; Sotocinal et al., 2011; Hampshire and Robertson, 2015; Dalla Costa et al., 2016). We observed that rats made grimaces after the administration of cisplatin; therefore, we hypothesized that changes in facial expression can be used as a method to evaluate the nausea-like response in rats.

Clinically, cisplatin-induced acute nausea occurs within 2 h and peaks at about 5–6 h after drug administration (Navari and Aapro, 2016). Delayed nausea begins more than 24 h after drug administration, and the intensity of this delayed nausea peaks at around 48 h and persists for about a week (Navari and Aapro, 2016). In this study, we observed that the administration of both doses of cisplatin induced a significant decrease of the eye-opening index in rats. The changes in the facial expression occurred 3 h after administration, and they were observed on the following day. The time required to induce these changes is similar to the latency of cisplatin-induced nausea in humans. Furthermore, we observed that rats pretreated with anti-emetic drugs did not show these changes and pica behavior induced by the lower dose of cisplatin. On the other hand, although we could not evaluate the effect of the higher dose of cisplatin based on pica behavior due to suppression of their behavior; we confirmed that rats treated with cisplatin at a dose of 6 mg/kg exhibited a decrease of the eye-opening index, and the decrease was significantly greater than that in rats administered cisplatin at a dose of 3 mg/kg. The therapeutic effects of anti-emetic drugs on the acute and delayed phases of the cisplatin-induced decrease of the eye-opening index in rats that received an even higher dose of cisplatin were maintained in our study. Based on these results, it is possible that the changes in the eye-opening index are also useful for assessing the nausea-like response in laboratory animals.

In this study, we found that single-treatment with fosaprepitant significantly inhibited the cisplatin-induced decrease of the eye-opening index in rats at both doses. We previously reported that substance P is predominantly involved in cisplatin-induced pica in rats, and an NK₁ receptor
antagonist is considered to be the most effective treatment for a chemotherapy-induced nausea-like response in rats (Yamamoto et al., 2014); however, we recognize that NK1 receptor antagonists are clinically used in combination with other anti-emetic drugs such as 5-HT3 receptor antagonists and/or corticosteroids. It will be necessary to determine the responsible etiology and establish effective treatment for the nausea-like response in laboratory animals other than rats by this method.

The administration of cisplatin is known to induce peripheral neuropathic pain (Jaggi and Singh, 2012). Since Sotocinal et al. (2011) reported that rats suffering spontaneous pain had a tendency to close their eyes, it is considered to be difficult to distinguish accurately between a nausea-like response and neuropathic pain. Seto et al. (2016) reported that rats treated with cisplatin at a dose of 4 mg/kg showed mechanical allodynia on day 6 after the administration. Joseph and Levine (2009) reported that cisplatin-induced hyperalgesia had a latency to onset of about 2 days, and it was maximal by 3–4 days. From these findings, since the results of this study are not considered to be due to the early development of neuropathy, which would probably require more time to occur, they may indicate a method for the detection of the nausea-like response in rats. We previously reported that copper sulfate, lithium chloride, and teriparatide (parathyroid hormone analog) transiently increased only kaolin consumption without affecting food consumption in rats (Yamamoto et al., 2004, 2015).

Takeda et al. (1986) reported that rotation stimulation induced pica behavior in rats. Further experiments will be needed to determine the change in the eye-opening index induced by these emetogenic stimuli, that are considered to have a short latency and short-term effect, in order to distinguish between a nausea-like response and neuropathic pain.

An advantage of our developed method is that we can collect data related to a series of continuous behaviors of rats under physiological conditions because we use an infrared camera in order to record the facial expression. Furthermore, this method can be applied to other animal species such as mice, ferrets, and Suncus murinus as well as rats. A previous study demonstrated that automatic detection of vomiting in Suncus murinus (house musk shrew) was possible by the detection of contour deformation (Huang et al., 2011). Thus, it may be possible to detect nausea and vomiting simultaneously by combining these systems.

In summary, the results suggest that the changes in the facial expression have the potential to be useful for the detection of a nausea-like response in laboratory animals.

ETHICS STATEMENT

All experiments were approved by the Animal Care Committee of the School of Allied Health Sciences, Faculty of Medicine, Osaka University (26-05-01), and were conducted in accordance with the Animal Experiment Guidelines of Osaka University.

AUTHOR CONTRIBUTIONS

KY, ST, and TI designed the experiments. KY and ST performed the experiments and data analysis.

ACKNOWLEDGMENT

This study was supported by JSPS KAKENHI Grant Number JP26670268.

REFERENCES

Andrews, P. L., and Horn, C. C. (2006). Signals for nausea and emesis: implications for models of upper gastrointestinal diseases. Auton. Neurosci. 125, 100–115. doi: 10.1016/j.autneu.2006.01.008

Bloechl-Daum, B., Deuson, R. R., Mavros, P., Hansen, M., and Herrstedt, J. (2006). Delayed nausea and vomiting continue to reduce patients’ quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J. Clin. Oncol. 24, 4472–4478. doi: 10.1200/JCO.2006.05.6382

Cabezos, P. A., Vera, G., Castillo, M., Fernández-Pujol, R., Martin, M. I., and Abalo, R. (2008). Radiological study of gastrointestinal motor activity after acute cisplatin in the rat. Temporal relationship with pica. Auton. Neurosci. 141, 54–65. doi: 10.1016/j.autneu.2008.05.004

Dalla Costa, E., Stucke, D., Dai, F., Minero, M., Leach, M. C., and Lebelt, D. (2016). Using the horse grimace scale (HGS) to assess pain associated with acute laminitis in horses (Equus caballus). Animals (Basel) 6:47. doi: 10.3390/ani6080047

du Bois, A., Meerpoil, H. G., Vach, W., Kommoss, F. G., Fenzl, E., and Pfleiderer, A. (1992). Course, patterns, and risk-factors for chemotherapy-induced emesis in cisplatin-pretreated patients: a study with ondansetron. Eur. J. Cancer 28, 450–457. doi: 10.1016/0959-8049(90)90075-9

Einhorn, L. H., Rapoport, B., Navari, R. M., Herrstedt, J., and Brames, M. J. (2016). 2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting. Support Care Cancer 25, 303–308. doi: 10.1007/s00520-016-3449-y

Farrell, C., Brearley, S. G., Pilling, M., and Molassiotis, A. (2013). The impact of chemotherapy-related nausea on patients’ nutritional status, psychological distress and quality of life. Support Care Cancer 21, 59–66. doi: 10.1007/s00520-012-1493-9

Florczyk, A. P., Schurig, J. E., and Bradner, W. T. (1982). Cisplatin-induced emesis in the Ferret: a new animal model. Cancer Treat. Rep. 66, 187–189.

Hampshire, V., and Robertson, S. (2015). Using the facial grimace scale to evaluate rabbit wellness in post-procedural monitoring. Lab. Anim. (N.Y.) 44, 259–260. doi: 10.1038/lab.an.806

Hatcher, R. A. (1924). Mechanism of vomiting. Physiol. Rev. 4, 479–504.

Hendey, G. W., Donner, N. F., and Fuller, K. (2005). Clinically significant changes in nausea as measured on a visual analog scale. Ann. Emerg. Med. 45, 77–81. doi: 10.1016/j.annemergmed.2004.07.446

Huang, D., Meyers, K., Henry, S., De la Torre, F., and Horn, C. C. (2011). Computerized detection and analysis of cancer chemotherapy-induced emesis in a small animal model, musk shrew. J. Neurosci. Methods 197, 249–258. doi: 10.1016/j.neumeth.2011.02.032

Jaggi, A. S., and Singh, N. (2012). Mechanisms in cancer-chemotherapeutic drugs-induced peripheral neuropathy. Toxicology 291, 1–9. doi: 10.1016/j.tox.2011.10.019

Jordan, K., Jahn, F., and Aapro, M. (2015). Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review. Ann. Oncol. 26, 1081–1090. doi: 10.1093/annonc/mdv138

Joseph, E. K., and Levine, J. D. (2009). Comparison of oxaliplatin- and cisplatin-induced painful peripheral neuropathy in the rat. J. Pain 10, 534–541. doi: 10.1016/j.jpain.2008.12.003
King, G. L. (1990). Animal models in the study of vomiting. Can. J. Physiol. Pharmacol. 68, 260–268. doi: 10.1139/y90-040
Langford, D. J., Bailey, A. L., Chanda, M. L., Clarke, S. E., Drummond, T. E., Echols, S., et al. (2010). Coding of facial expressions of pain in the laboratory mouse. Nat. Methods 7, 447–479. doi: 10.1038/nmeth.1455
Malik, N. M., Liu, Y. L., Cole, N., Sanger, G. J., and Andrews, P. L. (2007). Differential effects of dexamethasone, ondansetron and a tachykinin NK1 receptor antagonist (GR205171) on cisplatin-induced changes in behaviour, food intake, pica and gastric function in rats. Eur. J. Pharmacol. 555, 164–173. doi: 10.1016/j.ejphar.2006.10.043
Malik, N. M., Moore, G. B., Smith, G., Liu, Y. L., Sanger, G. J., and Andrews, P. L. (2006). Behavioural and hypothalamic molecular effects of the anti-cancer agent cisplatin in the rat: a model of chemotherapy-related malaise? Pharmacol. Biochem. Behav. 83, 9–20. doi: 10.1016/j.pbb.2005.11.017
Molassiotis, A., Saunders, M. P., Valle, J., Wilson, G., Lorigan, P., Wardley, A., et al. (2008). A prospective observational study of chemotherapy-related nausea and vomiting in routine practice in a UK cancer centre. Support Care Cancer 16, 201–208. doi: 10.1007/s00520-007-0343-7
Natale, J. J. (2015). Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis. Hosp. Pract. 43, 226–234. doi: 10.1080/21548331.2015.1077095
Navari, R. M. (2015). Treatment of breakthrough and refractory chemotherapy-induced nausea and vomiting. BioMed. Res. Int. 2015:595894. doi: 10.1155/2015/595894
Navari, R. M., and Aapro, M. (2016). Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting. N. Engl. J. Med. 374, 1156–1167. doi: 10.1056/NEJMra151542
Parker, L. A. (2014). Conditioned flavor avoidance, and conditioned gaping: rat models of conditioned nausea. Eur. J. Pharmacol. 722, 122–133. doi: 10.1016/j.ejphar.2013.09.070
Quigley, E. M., Hasler, W. L., and Parkman, H. P. (2001). AGA technical review on nausea and vomiting. Gastroenterology 120, 263–286. doi: 10.1053/gast.2001.20516
Ripamonti, C. I. (2012). Pain management. Ann. Oncol. 23(Suppl. 10), x294–x301. doi: 10.1093/annonc/mds360
Scallan, E. M., and Simon, B. T. (2016). The effects of acupuncture point Pericardium 6 on hydromorphone-induced nausea and vomiting in healthy dogs. Vet. Anaesth. Analg. 43, 495–501. doi: 10.1111/vaa.12347
Seto, Y., Okazaki, F., Horikawa, K., Zhang, J., Sasaki, H., and To, H. (2016). Influence of dosing times on cisplatin-induced peripheral neuropathy in rats. BMC Cancer 16:756. doi: 10.1186/s12885-016-2777-0
Sotocinal, S. G., Sorge, R. E., Zaloum, A., Tuttle, A. H., Martin, L. J., Wieskopf, J. S., et al. (2011). The Rat grimace scale: a partially automated method for quantifying pain in the laboratory rat via facial expressions. Mol. Pain 7:55. doi: 10.1186/1744-8069-7-55
Takeda, N., Morita, M., Kubo, T., Yamatodani, A., Watanabe, T., Wada, H., et al. (1986). Histaminergic mechanism of motion sickness. Neurochemical and neuroparmacological studies in rats. Acta Otolaryngol. 101, 416–421.
Ueno, S., Matsuuki, N., and Saito, H. (1987). Suncus murinus: a new experimental model in emesis research. Life Sci. 41, 513–518. doi: 10.1016/0024-3205(87)90229-3
Wewers, M. E., and Lowe, N. K. (1990). A critical review of visual analogue scales in the measurement of clinical phenomena. Res. Nurs. Health 13, 227–236. doi: 10.1002/nur.4770130405
Yamamoto, K., Asano, K., Matsuoka, N., Imaizumi, M., and Yamatodani, A. (2011). Time-course analysis of pica using an automatic feeding monitoring system. J. Pharmacol. Toxicol. Methods. 63, 30–34. doi: 10.1016/j.vascn.2010.04.011
Yamamoto, K., Asano, K., Tasaka, A., Ogura, Y., Kim, S., Ito, Y., et al. (2014). Involvement of substance P in the development of cisplatin-induced acute and delayed pica in rats. Br. J. Pharmacol. 171, 2888–2899. doi: 10.1111/bph.12629
Yamamoto, K., Kato, N., Isogai, Y., Kuroda, T., Ishida, T., and Yamatodani, A. (2015). Induction and antagonism of pica induced by teriparatide in rats. Eur. J. Pharmacol. 764, 457–462. doi: 10.1016/j.ejphar.2015.07.039
Yamamoto, K., Nakai, M., Nohara, K., and Yamatodani, A. (2007). The anti-cancer drug-induced pica in rats is related to their clinical emetogenic potential. Eur. J. Pharmacol. 554, 34–39. doi: 10.1016/j.ejphar.2006.09.058
Yamamoto, K., Ngan, M. P., Takeda, N., Yamatodani, A., and Rudd, J. A. (2004). Differential activity of drugs to induce emesis and pica behavior in Suncus murinus (house musk shrew) and rats. Physiol. Behav. 83, 151–156. doi: 10.1016/S0031-9384(04)00332-4
Yamamoto, K., Yamamoto, E., Sugimoto, T., Sakagami, T., and Yamatodani, A. (2016). Sevoflurane-induced pica in female rats. J. Pharmacol. Sci. 131, 68–71. doi: 10.1016/j.jphs.2016.03.015

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The reviewer GV and handling Editor declared their shared affiliation, and the handling Editor states that the process nevertheless met the standards of a fair and objective review.

Copyright © 2017 Yamamoto, Tatsutani and Ishida. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.